All In Biotech

Drug Trial Radar · NCT04609878

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter Variable Length Study to Assess the Efficacy and Safety of PT010 Relative to PT009 and Symbicort® in Adult and Adolescent Participants With Inadequately Controlled Asthma

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,274 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,274

Actual

Start

Dec 15, 2020

Primary completion

Mar 21, 2025

Study completion Mar 21, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care

Conditions

  • Asthma

Interventions

  • BGF MDI 320/28.8/9.6 μgDrug

    Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler

  • BGF MDI 320/14.4/9.6 μgDrug

    Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler

  • BFF MDI 320/9.6 μgDrug

    Budesonide and formoterol fumarate metered dose inhaler

  • BFF pMDI 320/9 μgDrug

    Budesonide/formoterol fumarate pressurized metered dose inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in FEV1 AUC0-3 (L) at Week 24Time frame: Week 24
  2. Pooled (KALOS/LOGOS): Rate of Severe Asthma ExacerbationsTime frame: Up to 52 weeks

Locations

360 sites in 21 countries. Site status is shown where the registry gives one.

  • Research Site

    Saraland, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Sun City West, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Covina, California

  • Research Site

    Encinitas, California

  • Research Site

    Fresno, California

  • Research Site

    Laguna Hills, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Mission Hills, California

  • Research Site

    Newport Beach, California

  • Research Site

    Northridge, California

  • Research Site

    San Diego, California

  • Research Site

    Stockton, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Upland, California

  • Research Site

    Westminster, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Lakewood, Colorado

  • Research Site

    Brandon, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Adairsville, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Columbus, Georgia

  • Research Site

    Lawrenceville, Georgia

  • Research Site

    Rincon, Georgia

  • Research Site

    Savannah, Georgia

  • Research Site

    Tyrone, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    River Forest, Illinois

  • Research Site

    Brownsburg, Indiana

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Louisville, Kentucky

  • Research Site

    Crowley, Louisiana

Showing 40 of 360 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.